Sildenafil in pulmonary hypertension [1]

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 22, Issue 1, 2005, Pages 78-79

  Della Torre, Fabrizio ^a   Della Torre, Emanuel ^a   Di Berardino, Federica ^b  

^a INRCA   (Italy)

^b ASL of Milan   (Italy)

Author keywords

Hypertension; Oxygen inhalation therapy; Phosphodiesterase inhibitors; Pulmonary; Sildenafil

Indexed keywords

SILDENAFIL;

AGED; ARTERY MUSCLE; CASE REPORT; DRUG EFFICACY; HUMAN; LETTER; LUNG FUNCTION; M MODE ECHOCARDIOGRAPHY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SMOOTH MUSCLE FIBER;

ACTIVITIES OF DAILY LIVING; AGED; DISEASE PROGRESSION; DYSPNEA; HUMANS; HYPERTENSION, PULMONARY; MALE; PIPERAZINES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 15944399706     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (7)

1. Dorfmüller P, Humbert M, Capron F, Müller K: Pathology and aspects of pathogenesis in pulmonary arterial hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2003;20:9-19.
2. Michelakis ED: The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension. Heart Fail Rev 2003; 8: 5-21.
3. Wilkins MR: Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001; 104: 424-8.
4. Sebkhi A, Strange JW, Phillips SC, et al: Phosphodiesterase Type 5 as a Target for the Treatment of Hypoxia-Induced Pulmonary Hypertension. Circulation 2003; 107: 3230-5.
5. Carroll WD, Dhillon R: Sildenafil as a treatment for pulmonary hypertension. Arch Dis Child 2003; 88: 827-8.
6. Rubin LJ, Badesch DB, Barst RJ, et al: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
7. Michelakis ED, Tymchak W, Webster L, et al: Long-term treatment with oral Sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003; 108: 2066-9.